List view / Grid view
19 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from RECLAIM-1 and RECLAIM-2, the pivotal Phase III studies investigating the potential of the antibiotic ceftazidime-avibactam (CAZ-AVI) as a treatment for hospitalised adult patients with complicated intra-abdominal infections...
19 August 2014 | By Amgen
Amgen announced that a second placebo-controlled Phase 3 study evaluating AMG 416 for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease, receiving hemodialysis, met its primary and all secondary endpoints...
18 August 2014 | By Daiichi Sankyo
Daiichi Sankyo Company, Limited announced the start of the Phase 3 trial of CHS-0214, an investigational etanercept biosimilar1, in rheumatoid arthritis (the RApsody trial) in Japan...
18 August 2014 | By Biogen Idec
Biogen Idec announced that the U.S. Food and Drug Administration has approved PLEGRIDYTM (peginterferon beta-1a), a new treatment for people with relapsing forms of multiple sclerosis...
15 August 2014 | By Roche
Avastin is the first biologic medicine approved in combination with chemotherapy to help women with this type of cancer live longer than with chemotherapy alone...
15 August 2014 | By Amgen
Amgen and its subsidiary, Onyx Pharmaceuticals, Inc., announced that the Phase 3 clinical trial FOCUS did not meet its primary endpoint of improving overall survival...
15 August 2014 | By Pfizer
Pfizer Inc. announced that the U.S. Food and Drug Administration has accepted for review the Biologics License Application for bivalent recombinant LP2086...
14 August 2014 | By Sanofi
Sanofi Pasteur announced that The New England Journal of Medicine published positive results from a large-scale, multi-center efficacy trial, which found that Fluzone® High-Dose (Influenza Vaccine) was more efficacious in preventing influenza...
14 August 2014 | By AstraZeneca
AstraZeneca announced the start of the Phase III programme for tralokinumab, a potential treatment for patients with severe, inadequately controlled asthma, developed by MedImmune, the company’s global biologics research and development arm...
14 August 2014 | By Pfizer
Pfizer Inc. announced that the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to recommend Prevnar 13®...
14 August 2014 | By Amgen
Amgen initiated a voluntary recall on June 26, 2014 for nine packaged lots of Aranesp® (darbepoetin alfa) (500 mcg) prefilled syringes from non-U.S. distributors, wholesalers and a number of hospital pharmacies...
14 August 2014 | By AstraZeneca
AstraZeneca announced positive top-line results from CLEAR1, CLEAR2 and CRYSTAL, the pivotal Phase III clinical trials investigating the potential of lesinurad...
12 August 2014 | By Sanofi
Sanofi and MannKind Corporation announced that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder...
11 August 2014 | By Novartis
New data revealing the reduction in cardiovascular deaths with Novartis' LCZ696 in patients with heart failure with reduced ejection fraction (HF-REF) will be presented at the world's largest cardiology congress...
11 August 2014 | By Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim overcame major challenges in the first half of 2014...
